Our study also assessed whether the use of CPI-455 KDM5 inhibitor may provide preclinical mechanistic evidence supporting future development of KDM5B inhibitors to suppress androgen signaling in PCa (Vinogradova et al., 2016). Here, KDM5B is linked to posterior cortical atrophy.